These findings offer conceptually novel insights into the development and pathogenesis of IBD and CAC by revealing the role of the TGF‐β/Smad4 disruption in shaping the immune response, which have therapeutic implications on IBD and colitis‐associated tumorigenesis. Here, TGFB1 is linked to inflammatory bowel disease.